MEDICINOVA INC Files 10-K for Fiscal Year Ended December 31, 2023

TL;DR

<b>MEDICINOVA INC has filed its annual 10-K report for the fiscal year ending December 31, 2023, detailing its business operations and financial standing.</b>

AI Summary

MEDICINOVA INC (MNOV) filed a Annual Report (10-K) with the SEC on February 15, 2024. MEDICINOVA INC filed its 10-K report for the fiscal year ending December 31, 2023. The company's principal business address is located at 4275 Executive Square, Suite 300, La Jolla, CA 92037. MEDICINOVA INC is incorporated in Delaware and operates within the Pharmaceutical Preparations industry (SIC 2834). The filing references various financial instruments and equity plans, including Certificates of Deposit, Employee Stock Options, and Additional Paid-In Capital. Key dates and events related to equity incentive plans and sales agreements are noted, such as the Two Thousand Nineteen At Market Issuance Sales Agreement dated August 23, 2019.

Why It Matters

For investors and stakeholders tracking MEDICINOVA INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of MEDICINOVA INC's financial performance, operational activities, and strategic initiatives for the fiscal year 2023, which is crucial for investors to assess the company's current health and future prospects. The detailed information on financial instruments, equity plans, and expenses like Research and Development is essential for understanding the company's investment in innovation and its capital structure.

Risk Assessment

Risk Level: medium — MEDICINOVA INC shows moderate risk based on this filing. The filing is a standard 10-K, which typically contains a broad range of information. However, without specific financial performance data or forward-looking statements within the provided snippet, it's difficult to assess the company's immediate financial health or growth trajectory, necessitating a medium risk assessment.

Analyst Insight

Review the full 10-K filing to analyze MEDICINOVA INC's financial statements, risk factors, and management's discussion and analysis for a comprehensive understanding of its performance and outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (The end date of the reporting period for the 10-K.)
• 2024-02-15 — Filing Date (The date the 10-K was filed with the SEC.)
• 858-373-1500 — Business Phone (Contact phone number for MEDICINOVA INC.)
• 001-33185 — SEC File Number (The SEC file number associated with MEDICINOVA INC.)
• 24644193 — Film Number (The film number for the filing.)
• 2019-08-23 — Sales Agreement Date (Date of the Two Thousand Nineteen At Market Issuance Sales Agreement.)

Key Players & Entities

• MEDICINOVA INC (company) — Filer and subject of the 10-K report.
• 2023-12-31 (date) — Conformed period of report for the 10-K filing.
• 2024-02-15 (date) — Filed as of date for the 10-K filing.
• La Jolla, CA (location) — City and State of the company's business and mailing address.
• 2834 (industry_code) — Standard Industrial Classification code for Pharmaceutical Preparations.
• mnov:BRileyFBRIncMember (company) — Mentioned in relation to a sales agreement.
• mnov:TwoThousandNineteenAtMarketIssuanceSalesAgreementMember (agreement) — Specific sales agreement mentioned with a date.
• mnov:GenzymeCorporationMember (company) — Mentioned in relation to product development or licensing.

FAQ

Risk Factors

• Regulatory Compliance [medium — regulatory]: The company operates in the pharmaceutical industry, which is subject to extensive regulation by government agencies.
• Financial Performance [medium — financial]: The company's financial results are subject to market fluctuations and the success of its product development pipeline.
• Product Development Risks [high — operational]: Risks associated with the development, testing, and commercialization of pharmaceutical products.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share MNOV The Nasdaq Stock Mar
• $2.30 — on stock on the NASDAQ Global Market of $2.30 per share on June 30, 2023. Sh ares of

Filing Documents

• mnov-20231231.htm (10-K) — 1824KB
• mnov-ex19_1.htm (EX-19.1) — 230KB
• mnov-ex23_1.htm (EX-23.1) — 4KB
• mnov-ex31_1.htm (EX-31.1) — 11KB
• mnov-ex31_2.htm (EX-31.2) — 11KB
• mnov-ex32_1.htm (EX-32.1) — 9KB
• mnov-ex32_2.htm (EX-32.2) — 9KB
• mnov-ex97_1.htm (EX-97.1) — 47KB
• 0000950170-24-015920.txt (&nbsp;) — 6948KB
• mnov-20231231.xsd (EX-101.SCH) — 857KB
• mnov-20231231_htm.xml (XML) — 1004KB

Business

Business 5 Item 1A

Risk Factors

Risk Factors 38 Item 1B Unresolved Staff Comments 67 Item 1C Cybersecurity 67 Item 2

Properties

Properties 68 Item 3

Legal Proceedings

Legal Proceedings 68 Item 4 Mine Safety Disclosures 68 PART II Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 69 Item 6 [Reserved] 69 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 70 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 75 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 75 Item 9 Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 96 Item 9A

Controls and Procedures

Controls and Procedures 96 Item 9B Other Information 97 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 98 PART III Item 10 Directors, Executive Officers and Corporate Governance 99 Item 11

Executive Compensation

Executive Compensation 99 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 99 Item 13 Certain Relationships and Related Transactions, and Director Independence 100 Item 14 Principal Accountant Fees and Services 100 PART IV Item 15 Exhibits and Financial Statement Schedules 101

Signatures

Signatures 104 The MediciNova logo is a registered trademark of MediciNova, Inc. All other product and company names are registered trademarks or trademarks of their respective companies. 2 PART I CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K includes forward-looking statements that involve a number of risks and uncertainties, many of which are beyond our control. The forward-looking statements are contained principally in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," but are also contained elsewhere in this report. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including those described in "Risk Factors" and elsewhere in this report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our beliefs and assumptions only as of the date of this report. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should read this report completely and with the understanding that our actual future results may be materially different from what we expect. T

B usiness

Item 1. B usiness Overview We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). Our pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. MN-166 (ibudilast) is in development for several different neurological diseases and other diseases as described below. 5 Progressive Multiple Sclerosis: We completed a Phase 2b clinical trial of MN-166 (ibudilast) for the treatment of relapsing multiple sclerosis (MS), in which positive safety and neuroprotective efficacy indicators were observed. The data from this trial indicated that MN-166 (ibudilast) may have potential in the treatment of progressive MS. We partnered with investigators on a Phase 2b clinical trial of MN-166 (ibudilast) in primary progressive and secondary progressive MS which was conducted by NeuroNEXT and funded by the National Institute of Health's (NIH) National Institute of Neurological Diseases and Stroke (NINDS). This progressive MS trial, known as SPRINT-MS, completed randomization of 255 subjects in 2015, which exceeded the goal of 250 subjects that were planned for participation. In October 2017, we announced the presentation of positive top-line resu

View Full Filing

View this 10-K filing on SEC EDGAR